Redeye shares its initial view on Modelon’s Q3 2025 report.
Redeye provides its initial take on Hansa Biopharma’s Q3 report.
Suominen had published some details of its Q3 earnings before the actual release in connection with ...
Dovre’s losses continued over Q3, as was known thanks to the yet another negative profit warning.
Redeye provides an update following Senzime’s Q3 2025 report.
Suominen's Q3 headline figures had been pre-announced in conjunction with the profit warning on 15 O...
Redeye presents its preview of RaySearch’s Q3 2025 results due on Friday, November 7.
Etteplan issued a profit warning yesterday alongside preliminary Q3 figures.
Suominen’s Q3 results were known beforehand since the company released preliminary information about...
Solteq’s Q3 fell slightly short of our expectations.
Suominen Q3 comparable EBITDA of EUR 3.4m and net sales of EUR 100m were pre-announced in connection...
Redeye provides an initial take following Senzime’s Q3 2025 report.
* Net sales SEK 529m, +2% vs ABGSCe, +3% vs Factset cons.
Redeye updates its production estimates for Arise ahead of its Q3 report, which is due on 6 November...
Taaleri's Q3 results came in clearly above our expectations on a group level, and performance on the...
Redeye provides an update following Truecaller’s Q3 2025 report, which came in below expectations du...
Vaxxa redovisade totala intäkter på 24,6 MSEK under Q3 2025, en ökning med 14 % mot föregående år.
* Adj. EBITA SEK 274m (+4% vs. ABG, +2% vs. IR consensus) * We expect consensus adj.
Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3.
Redeye comments on Truecaller’s Q3 2025 report, which came in softer than expected.
